Yuanbio Venture Capital is a venture capital firm that primarily focuses on early and growth-stage investments within the healthcare sector in China. Their investment strategy targets areas such as new drugs, biopharma, medical devices, in-vitro diagnostics, precision medicine, and health services.
100% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-b (50% of deals). Average disclosed round size is $43.0M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$1.1B
Top Stage
Series B
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| AAusperBio | Series B | $63M | Sep 2025 |
| AAusperBio | Series B | $50M | May 2025 |
| AAusperBio | Series A | $37M | Jul 2024 |
 Degron Therapeutics | Series A | $22M | Jun 2022 |
Top Co-Investors
Genesis Investments3 shared
CDH Investments2 shared
HanKang Capital2 shared
Med-Fine Capital1 shared
Dyee Capital1 shared
Last updated: 10 April 2026